BHV-1400
/ Biohaven
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
August 05, 2025
Study of BHV-1400 in IgA Nephropathy
(clinicaltrials.gov)
- P1 | N=10 | Recruiting | Sponsor: Biohaven Therapeutics Ltd. | Not yet recruiting ➔ Recruiting
Biomarker • Enrollment open • Glomerulonephritis • IgA Nephropathy • Renal Disease
July 08, 2025
Study of BHV-1400 in IgA Nephropathy
(clinicaltrials.gov)
- P1 | N=10 | Not yet recruiting | Sponsor: Biohaven Therapeutics Ltd.
Biomarker • New P1 trial • Glomerulonephritis • IgA Nephropathy • Renal Disease
May 12, 2025
Biohaven Reports First Quarter 2025 Financial Results and Recent Business Developments
(PRNewswire)
- "Expected Upcoming Milestones:...MoDE Platform: (i) IgG MoDE Degraders (1300/1310): BHV-1300 Phase 1 with the optimized subcutaneous formulation completing in 1H 2025. Expect to initiate Phase 1b study in Graves' disease in mid-2025, and additional programs in rheumatoid arthritis and myasthenia gravis continue to be pursued; (ii) Phase 1 studies with BHV-1400 and BHV-1600 expected to be completed in 1H 2025."
New P1 trial • Trial status • Grave’s Disease • Myasthenia Gravis • Rheumatoid Arthritis
March 03, 2025
Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2024 Financial Results
(PRNewswire)
- "IgG MoDE Degraders (1300/1310): BHV-1300 Phase 1 with the optimized subcutaneous formulation completing in 1H 2025. BHV-1310 completion of preclinical testing prior to anticipated FIH study initiating 1H 2025...Phase 1 with BHV-1400 and BHV-1600 expected to be completed in 1H 2025...Kv7 Activator (BHV-7000): Pivotal major depressive disorder topline results expected in 2H 2025. Focal epilepsy study topline results expected in 1H 2026."
Clinical data • Preclinical • Trial completion date • Epilepsy • IgA Nephropathy • Immunology • Major Depressive Disorder
1 to 4
Of
4
Go to page
1